Will Entresto's Price Decrease After Patent Expiration?
Why Have Entresto Prices Been High?
Entresto (Sacubitril/Valsartan) is a medication used to treat heart failure. Due to the patent-holding company Novartis, Entresto's prices have been relatively high [1].
Patent Expiration Timeline
According to DrugPatentWatch.com, Entresto's patent was set to expire in 2023 [2], allowing generic versions of the medication to enter the market. However, the first generic competition from pharmaceutical company Aurobindo Pharma was delayed [3].
Generic Competition and Price Decrease
When generic competition finally enters the market, it's possible that prices for Entresto could decrease significantly. Generic companies typically charge lower prices than branded manufacturers, and increased competition can drive prices down even further. Studies have shown that generic competition can lead to savings of up to 83% compared to the original brand-name medication [4].
Will Other Factors Affect Price Decrease?
Other factors could influence the eventual price of Entresto after patent expiration. These include changes in market competition, government policies and regulations, and the company's pricing strategy. However, assuming a typical generic competition scenario, prices are likely to decrease.
What Happens When Patent Expiration Approaches?
As Entresto's patent expiration date approaches, prices may start to reflect the impending competition. Manufacturers may reduce prices to maintain market share or offer discount programs to patients to retain loyalty.
Entresto's Exclusive Exclusivity Period
The exclusivity period for Entresto ended in December 2022 [5], which allowed the first generic competition to enter the market.
How Much Will Prices Decrease?
While difficult to predict, studies suggest that the prices of generic Entresto could be significantly lower than the original brand-name medication. With the first generic competition entering the market, prices may decrease by up to 60-80% [1].
Additional Considerations
Regulatory pressures, changes in healthcare policies, and the company's pricing strategies might affect the pricing of Entresto post-patent expiration. The impact of such factors can be complex and may alter the expected price dynamics.
Sources
[1] DrugPatentWatch.com. (2023). Entresto (Sacubitril/Valsartan) Patent Expiration.
[2] Statnews.com. (2023). Deciphering the tangled world of medication prices.
[3] Reuters. (2023). Court delays generic competition for Novartis’s Entresto.
[4] BMJ 2023;376:o172.
[5] FDA.gov. (2023). Exclusivity for Entresto (Sacubitril/Valsartan).